Novo Nordisk launches Wegovy subscription for GLP-1 obesity drugs
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images Novo Nordisk on Tuesday launched a…
ADHD medication in short supply in Japan as demand soars
Since last fall, Concerta, a medication used for the treatment of attention-deficit/hyperactivity disorder (ADHD), has been in short…
Eli Lilly reaches deal to bring AI-developed drugs to global market
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, Nov. 21,…
Every Cure’s drug repurposing could change rare disease treatment
Dr. David Fajgenbaum, one of the founders of Every Cure, a nonprofit focused on drug repurposing. Courtesy of…
FDA approves new ‘Wegovy HD’ with triple the dosage of the semaglutide medication
The US Food and Drug Administration announced on Thursday its approval of a new, higher-dose Wegovy (semaglutide) injection.…
Pfizer Lyme disease vaccine fails trial, company to seek FDA approval
Thomas Fuller | Nurphoto | Getty Images Pfizer on Monday said it will seek regulatory approval for a…
How CNBC Cures is bringing rare disease stories to a national audience
Last summer, my sister Becky approached me with an idea. She wanted my help building a platform at…
How GLP-1 effectiveness is messing up new drug trials
The GLP-1 PR has been a little too good. Everyone knows the drugs lead to rapid weight loss…
Ozempic is getting generics as low as $15 — what it means for Americans
The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the…
FDA approves high dose version of Novo Nordisk’s obesity drug Wegovy
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark,…
Europe’s healthcare – A right or a business model? MEPs face off in The Ring
Published on 18/03/2026 – 21:30 GMT+1 Did you know that the price of a pill and the waiting…
Eli Lilly’s obesity drug retatrutide clears late-stage diabetes trial
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike…